Study S000584

Efficacy and Safety of Semaglutide 1.0 mg Once-weekly Versus Liraglutide 1.2 mg Once-daily as add-on to 1-3 Oral Anti-diabetic Drugs (OADs) in Subjects With Type 2 Diabetes

Included trial: extracted data ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT03191396
Acronym: SUSTAIN 10
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 577
Start: 2017-06-27
Primary completion: 2018-07-09
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:Semaglutide; DRUG:Liraglutide
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: REGISTRY:2016-004965-22; OTHER:U1111-1190-5868; NIH:2016

Registered primary outcomes

Change in HbA1c [Week 0, week 30]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0012216	Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2-4 and 10. Capehorn M, Diabetes therapy : research, treatment and education of diabetes and related disorders	2020	Randomized trial	PMID 32193837 DOI	cites ClinicalTrials.gov:NCT03191396; registry reference DERIVED:32193837
R0019465	Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Capehorn MS, Diabetes & metabolism	2020	Randomized trial	PMID 31539622 DOI	registry reference RESULT:31539622